After seeing both of these recent ann's (CannTab and Technion update), I have returned to securing a long position in the stock.
2 things I liked in yesterday's ann, particularly:
1. What appears to be a maturity in decision making by management to assess current research spend, with what may have been an extension of funding timelines in Israel. IMO, this seems to follow and be in line with their policy to preserve shareholder funds vs cash burn for the sake of "bragging rights".
2. Signed an agreement with a well known Australian medical research University and the NCIM Research Institute, to bring the research to Australia, giving CGB access to govt funding grants for MS research and potentially reduce large investment spends.
